X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32) 32
female (28) 28
male (28) 28
index medicus (25) 25
middle aged (25) 25
adult (23) 23
gastroenterology & hepatology (20) 20
drug therapy, combination (18) 18
hepatitis c (18) 18
gastroenterology and hepatology (17) 17
hepatitis c, chronic - drug therapy (16) 16
treatment outcome (16) 16
aged (15) 15
genotype (14) 14
hepacivirus - genetics (14) 14
hepatitis c virus (14) 14
interferon-alpha - administration & dosage (13) 13
interferon-alpha - adverse effects (13) 13
ribavirin - administration & dosage (13) 13
ribavirin - adverse effects (13) 13
hepatitis c, chronic - virology (12) 12
polyethylene glycols - administration & dosage (12) 12
polyethylene glycols - adverse effects (12) 12
proline - analogs & derivatives (12) 12
ribavirin (12) 12
ribavirin - therapeutic use (12) 12
antiviral agents - administration & dosage (11) 11
interferon-alpha - therapeutic use (11) 11
polyethylene glycols - therapeutic use (11) 11
recombinant proteins - administration & dosage (11) 11
recombinant proteins - adverse effects (10) 10
adolescent (9) 9
antiviral agents - adverse effects (9) 9
antiviral agents - therapeutic use (9) 9
drug therapy (9) 9
interferon (9) 9
recombinant proteins - therapeutic use (9) 9
abridged index medicus (8) 8
health aspects (8) 8
life sciences (8) 8
medical colleges (8) 8
proline - administration & dosage (8) 8
care and treatment (7) 7
combination therapy (7) 7
genetic aspects (7) 7
hepatitis (7) 7
plus ribavirin (7) 7
rna, viral - blood (7) 7
telaprevir (7) 7
virus diseases (7) 7
analysis (6) 6
anemia (6) 6
chronic hepatitis-c (6) 6
genotype 1 infection (6) 6
hepatitis c - drug therapy (6) 6
proline - adverse effects (6) 6
randomized-trial (6) 6
therapy (6) 6
viral load (6) 6
virus-infection (6) 6
article (5) 5
boceprevir (5) 5
digestive system diseases (5) 5
dose-response relationship, drug (5) 5
double-blind method (5) 5
peginterferon alpha-2b (5) 5
proline - therapeutic use (5) 5
recombinant proteins (5) 5
retrospective studies (5) 5
risk factors (5) 5
[ sdv ] life sciences [q-bio] (4) 4
alpha-2a (4) 4
amphotericin-b (4) 4
antifungal agents - therapeutic use (4) 4
antiviral agents (4) 4
complications and side effects (4) 4
dosage and administration (4) 4
hepacivirus - classification (4) 4
hepacivirus - drug effects (4) 4
infectious diseases (4) 4
interleukins - genetics (4) 4
itraconazole (4) 4
logistic models (4) 4
medical research (4) 4
medicine, general & internal (4) 4
microbiology (4) 4
prevalence (4) 4
protease inhibitors (4) 4
research (4) 4
sustained virological response (4) 4
time factors (4) 4
treatment failure (4) 4
triazoles - therapeutic use (4) 4
young adult (4) 4
anemia - chemically induced (3) 3
antifungal agents - administration & dosage (3) 3
antiviral therapy (3) 3
articles and commentaries (3) 3
biological response modifiers (3) 3
clinical trial (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9742, pp. 705 - 716
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2009, Volume 361, Issue 6, pp. 580 - 593
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 01/2007, Volume 356, Issue 4, pp. 335 - 347
Journal Article
Hepatology, ISSN 0270-9139, 03/2013, Volume 57, Issue 3, pp. 974 - 984
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 1/2007, Volume 44, Issue 1, pp. 2 - 12
Journal Article
Gastroenterology, ISSN 0016-5085, 2010, Volume 139, Issue 1, pp. 120 - 129.e18
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2014, Volume 60, Issue 4, pp. 748 - 756
Journal Article
Gastroenterology, ISSN 0016-5085, 2012, Volume 143, Issue 3, pp. 608 - 618.e5
Background & Aims Little is known about factors associated with a sustained virologic response (SVR) among patients with hepatitis C virus (HCV) infection to... 
Gastroenterology and Hepatology | Genetic | Response to Therapy | Clinical Trial | Prognostic Factors | GENETIC-VARIATION | IL28B | PLUS RIBAVIRIN | PEGINTERFERON ALPHA-2B | GENOTYPE 1 INFECTION | GASTROENTEROLOGY & HEPATOLOGY | Recombinant Proteins - therapeutic use | Multivariate Analysis | Prospective Studies | Hepatitis C - drug therapy | United States | Humans | Hepacivirus - genetics | Male | RNA, Viral - blood | Polyethylene Glycols - therapeutic use | Viral Load | Interleukins - genetics | Time Factors | Adult | Female | Drug Therapy, Combination | Odds Ratio | Hepacivirus - drug effects | Proline - analogs & derivatives | Risk Assessment | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Risk Factors | Interferon-alpha - therapeutic use | Genotype | Hepatitis C - genetics | Logistic Models | Treatment Outcome | Biomarkers - blood | Canada | Hepatitis C - diagnosis | Proline - therapeutic use | Phenotype | Interferon alpha-2 | Hepacivirus - growth & development | Polymorphism, Single Nucleotide | Virus diseases | Medical research | Medical colleges | Interleukins | Protease inhibitors | Medicine, Experimental | Thrombin | Rivers | Biological response modifiers | Hepatitis C virus | Health aspects | Consulting services | Analysis | Biological Markers | Proline | Recombinant Proteins | Ribavirin | Life Sciences | Hépatology and Gastroenterology | Polyethylene Glycols | Interferon-alpha | Antiviral Agents | Human health and pathology | RNA, Viral | Hepatitis C | Hepacivirus
Journal Article
Hepatology (Baltimore, Md.), ISSN 0270-9139, 2010, Volume 52, Issue 4, pp. 1201 - 1207
Journal Article
Journal Article